Topic: return on investment
J&J, Merck, Pfizer and Abbott reaped a combined $7 billion in savings from two tax reform provisions, and they spent most of it on investor payouts.
Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer now, its future pharma growth could be in jeopardy.
Government warns drugmakers could leave the UK if the country's separation from the EU drags on and is kept under wraps.